For research use only. Not for therapeutic Use.
PF-06761281 (Compound 4a) is a potent, orally active, partial selective sodium-coupled citrate transporter (NaCT or SLC13A5) inhibitor with IC50 values of 0.51, 13.2 and 14.1 µM against HEKNaCT, HEKNaDC1 and HEKNaDC3, respectively[1].
PF-06761281 (Compound 4a) inhibits citrate uptake with IC50 values of 0.12, 0.21 and 0.74 µM in rat, mouse and human Heps[1].
| Catalog Number | I034498 |
| CAS Number | 1854061-19-0 |
| Synonyms | (2R)-2-hydroxy-2-[2-(2-methoxy-5-methylpyridin-3-yl)ethyl]butanedioic acid |
| Molecular Formula | C13H17NO6 |
| Purity | ≥95% |
| InChI | InChI=1S/C13H17NO6/c1-8-5-9(11(20-2)14-7-8)3-4-13(19,12(17)18)6-10(15)16/h5,7,19H,3-4,6H2,1-2H3,(H,15,16)(H,17,18)/t13-/m1/s1 |
| InChIKey | FGYMJXFSHBLHLW-CYBMUJFWSA-N |
| SMILES | CC1=CC(=C(N=C1)OC)CCC(CC(=O)O)(C(=O)O)O |
| Reference | [1]. Huard K, et al. Optimization of a Dicarboxylic Series for in Vivo Inhibition of Citrate Transport by the Solute Carrier 13 (SLC13) Family. J Med Chem. 2016 Feb 11;59(3):1165-75. |
